Citigroup
NVO

Citigroup’s Novo Nordisk NVO Stock Holding History

Citigroup’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.01M Buy
218,000
+85,000
+64% +$4.03M ﹤0.01% 1608
2025
Q4 		$6.77M Buy
133,000
+10,000
+8% +$511K ﹤0.01% 1804
2025
Q3 		$6.83M Buy
123,000
+93,000
+310% +$5.44M ﹤0.01% 1767
2025
Q2 		$2.07M Hold
30,000
– – ﹤0.01% 2619
2025
Q1 		$2.08M Sell
30,000
-228,800
-88% -$18.9M ﹤0.01% 2668
2024
Q4 		$22.3M Buy
258,800
+231,300
+841% +$25M 0.01% 898
2024
Q3 		$3.27M Buy
+27,500
New +$3.67M ﹤0.01% 2216
2021
Q1 		– Sell
-92,800
Closed -$3.24M – 7043
2020
Q4 		$3.24M Buy
92,800
+26,400
+40% +$913K ﹤0.01% 2411
2020
Q3 		$2.31M Buy
66,400
+2,600
+4% +$86.7K ﹤0.01% 2527
2020
Q2 		$2.09M Sell
63,800
-8,800
-12% -$281K ﹤0.01% 2764
2020
Q1 		$2.19M Sell
72,600
-4,800
-6% -$143K ﹤0.01% 2391
2019
Q4 		$2.24M Sell
77,400
-62,600
-45% -$1.73M ﹤0.01% 2848
2019
Q3 		$3.62M Buy
140,000
+64,400
+85% +$1.63M ﹤0.01% 2232
2019
Q2 		$1.93M Buy
75,600
+20,200
+36% +$499K ﹤0.01% 2896
2019
Q1 		$1.45M Sell
55,400
-31,200
-36% -$767K ﹤0.01% 3000
2018
Q4 		$2M Buy
86,600
+24,400
+39% +$542K ﹤0.01% 2666
2018
Q3 		$1.47M Sell
62,200
-20,000
-24% -$488K ﹤0.01% 3067
2018
Q2 		$1.9M Buy
82,200
+54,800
+200% +$1.3M ﹤0.01% 2719
2018
Q1 		$674K Sell
27,400
-27,000
-50% -$709K ﹤0.01% 3677
2017
Q4 		$1.46M Sell
54,400
-5,400
-9% -$137K ﹤0.01% 2958
2017
Q3 		$1.44M Buy
59,800
+26,200
+78% +$592K ﹤0.01% 2996
2017
Q2 		$721K Sell
33,600
-28,800
-46% -$581K ﹤0.01% 3644
2017
Q1 		$1.07M Sell
62,400
-39,800
-39% -$693K ﹤0.01% 3145
2016
Q4 		$1.83M Buy
102,200
+8,800
+9% +$160K ﹤0.01% 3057
2016
Q3 		$1.94M Buy
93,400
+67,800
+265% +$1.68M ﹤0.01% 2542
2016
Q2 		$688K Buy
25,600
+18,600
+266% +$510K ﹤0.01% 3310
2016
Q1 		$190K Sell
7,000
-8,000
-53% -$214K ﹤0.01% 5137
2015
Q4 		$436K Buy
15,000
+11,200
+295% +$310K ﹤0.01% 3996
2015
Q3 		$103K Buy
3,800
+3,600
+1,800% +$102K ﹤0.01% 4963
2015
Q2 		$5K Buy
+200
New +$5.62K ﹤0.01% 6764

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Citigroup's NVO Position: Q1 2026 in Review

Citigroup increased its Novo Nordisk (NVO) stake by 10% in Q1 2026, buying an estimated $6.72M and bringing the position to 1,547,655 shares worth $56.9M. The position accounts for 0.02% of the portfolio, ranked #592.

Citigroup first reported a position in NVO in Q2 2013 and has held it in 52 quarters since. The position peaked at $190M in Q2 2024. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Citigroup held 1,547,655 shares of Novo Nordisk worth $56.9M as of Q1 2026.
  • Citigroup bought 141,931 Novo Nordisk shares in Q1 2026, an estimated $6.72M.
  • Novo Nordisk made up 0.02% of Citigroup's portfolio in Q1 2026, its #592 holding.
  • Citigroup first reported a position in Novo Nordisk in Q2 2013 and has held it in 52 quarters since.
  • Citigroup's Novo Nordisk position peaked at $190M in Q2 2024.
  • 1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.